• Excessive Calpain Impairs Offspring Cognition via BDNF/TrkB

  2026-05-09

  This study reveals that maternal non-obstetric surgery during pregnancy triggers excessive calpain activation in the developing rat hippocampus, leading to BDNF/TrkB pathway dysregulation and impaired cognitive outcomes in offspring. Pharmacological calpain inhibition with MDL 28170 or TrkB pathway stimulation partially rescues neuronal structure and function, highlighting new avenues for neuroprotection research.

• Sodium Ascorbate: Applied Workflows for Cancer Cell Assays

  2026-05-09

  Sodium Ascorbate, the mineral salt form of ascorbic acid, enables reproducible induction of intracellular ROS and selective necrotic tumor cell death, advancing glioblastoma multiforme research and broader cancer models. Here, we detail data-driven protocols, real-world troubleshooting, and how APExBIO’s Sodium Ascorbate uniquely addresses experimental challenges in oncology workflows.

• Hippo Signaling Modules Govern Hepatobiliary Cell Maturation

  2026-05-08

  This study uncovers how two independent Hippo pathway modules, HPO1 and HPO2, distinctly regulate the maturation and fate of hepatocytes and cholangiocytes in mouse liver development. By integrating spatial transcriptomics and advanced imaging, the authors reveal stage- and cell type-specific Hippo signaling control, reshaping our understanding of liver development and regeneration.

• Hippo Signaling Modules Govern Hepatobiliary Cell Fate and M

  2026-05-07

  This study reveals how spatially and temporally restricted Hippo signaling modules (HPO1 and HPO2) distinctly regulate the fate and maturation of hepatocytes and cholangiocytes in mouse liver development. The findings clarify the pathway’s nuanced role as a developmental checkpoint and suggest new approaches for dissecting cellular plasticity in liver regeneration and disease.

• Structural Insights into TRPM3 Modulation by Neurosteroids a

  2026-05-07

  Yin et al. provide cryo-EM structures elucidating how neurosteroids and the anticonvulsant primidone regulate the TRPM3 ion channel. Their findings clarify binding sites and gating mechanisms, offering a molecular basis for developing targeted therapies for pain and TRPM3-linked neurodevelopmental disorders.

• MLKL Polymerization Drives Lysosomal Membrane Permeabilizati

  2026-05-06

  This study uncovers how MLKL polymerization at lysosomal membranes initiates lysosomal membrane permeabilization (LMP), leading to cathepsin B release and necroptotic cell death. The findings clarify a key mechanistic link in regulated necrosis and provide new experimental entry points for dissecting cell death pathways.

• Apicidin as a Histone Deacetylase Inhibitor: Applied Workflo

  2026-05-06

  Harnessing Apicidin’s selectivity for HDAC3 and HDAC6, researchers can dissect chromatin regulation, cancer proliferation, and oocyte maturation at unprecedented resolution. This article translates the latest peer-reviewed findings and bench workflows into practical, data-driven protocols—empowering advanced labs to maximize Apicidin’s potential as an anti-proliferative and anti-angiogenesis compound.

• LG 101506: Precision RXR Modulation for Translational Oncolo

  2026-05-05

  This thought-leadership article explores how LG 101506, a synthetic RXR modulator from APExBIO, empowers translational researchers to interrogate nuclear receptor signaling and immune modulation in cancer models. By synthesizing mechanistic insight and recent evidence on immune checkpoint regulation in triple-negative breast cancer (TNBC), we provide a strategic roadmap for leveraging RXR pathway modulation to address key challenges in immunometabolic and oncology research. The article bridges rigorous experimental design, clinical relevance, and emerging perspectives on RXR-driven disease modeling.

• Neuroimaging Tracks hESC-Derived Dopaminergic Neuron Maturat

  2026-05-05

  Goggi et al. (2020) demonstrate that dopamine transporter (DAT) neuroimaging reliably assesses the maturation and functional integration of transplanted human embryonic stem cell-derived midbrain dopaminergic neurons in a preclinical Parkinson’s disease model. This approach offers a non-invasive, quantitative tool for evaluating cell therapies, with implications for translational research and protocol optimization.

• Early Life Adversity Weakens Visual Fear via Oxytocin Pathwa

  2026-05-04

  This study demonstrates that early life adversity, specifically social deprivation during a critical postnatal window, impairs innate defensive responses to visual threats in mice through oxytocin signaling deficits in the superior colliculus. The findings advance our mechanistic understanding of how early environment sculpts neural circuits for fear, with implications for neuropsychiatric risk and potential therapeutic directions.

• Azathramycin A: Advanced Mechanisms and Research Protocols

  2026-05-04

  Explore the unique mechanism of Azathramycin A, a macrolide antibiotic, in Mycobacterium tuberculosis research. This article delivers protocol insights and comparative perspectives for advanced antibacterial studies.

• DeferoxamineB: Iron Chelation Workflows in Cancer Research

  2026-05-03

  DeferoxamineB excels as a targeted iron chelator and apoptosis inducer, uniquely supporting metabolic intervention and regulated cell death assays in oncology. This article delivers stepwise protocol guidance, troubleshooting insights, and a synthesis of recent research advances to maximize reliability and innovation in applied cancer workflows.

• RNASEH1-AS1 as a Prognostic lncRNA Target in Hepatocellular

  2026-05-02

  This study identifies the long non-coding RNA RNASEH1-AS1 as an oncogenic driver and independent prognostic biomarker in hepatocellular carcinoma (HCC). Integrating bioinformatics and experimental validation, the authors reveal RNASEH1-AS1’s elevated expression, its association with poor outcomes, and its mechanistic interaction with DKC1.

• Selective FOXM1 Inhibition Overcomes Chemoresistance in Canc

  2026-05-02

  A recent study identified STL427944 as a novel, selective FOXM1 inhibitor that induces autophagic degradation of FOXM1 and sensitizes human cancer cells to standard chemotherapies including taxanes like Docetaxel. This work provides mechanistic insight into overcoming chemoresistance through targeted gene network analysis, advancing opportunities for more effective cancer chemotherapy research.

• Gepotidacin (GSK2140944): Optimizing Antibacterial Research

  2026-05-01

  Gepotidacin (GSK2140944) stands out as a first-in-class, dual-targeting bacterial DNA gyrase and topoisomerase IV inhibitor, uniquely addressing fluoroquinolone resistance. This article delivers actionable guidance for experimental design, troubleshooting, and advanced antibacterial research using Gepotidacin, leveraging the latest high-throughput screening and mechanistic insights.

16960 records 1/1131 page Next 12345 下5页 Last page